| Cat. No. |
Product Name |
Information |
| PC-26282 |
H018
JAK1/2 inhibitor
|
H018 (RAI-20) is a highly potent, selective JAK1/2 inhibitor with IC50 of 15.1/22.7 nM, >10-fold and 20-fold selective over JAK3 amd TYK2, displays robust anti-arthritic efficacy. |
| PC-26217 |
Deuruxolitinib
JAK1/2 inhibitor
|
Deuruxolitinib is the deuterated form of Ruxolitinib, is an orally active JAK1 and JAK2 inhibitor. |
| PC-26072 |
ARTS-011
Tyk2 inhibitor
|
ARTS-011 is a small-molecule allosteric inhibitor of Tyk2, selectively targeting the JH2 domain of the Tyk2 protein. |
| PC-26019 |
NS-229 hydrochloride
JAK1 inhibitor
|
NS-229 hydrochloride is a potent, selective JAK1 inhibitor with IC50 of 52 nM. |
| PC-26018 |
NS-229 4-methylbenzenesulfonate monohydrate
JAK1 inhibitor
|
NS-229 4-methylbenzenesulfonate monohydrate is a potent, selective JAK1 inhibitor with IC50 of 52 nM. |
| PC-25103 |
Voderdeucitinib
TYK2 inhibitor
|
Voderdeucitinib is a potent selective TYK2 inhibitor. |
| PC-25095 |
Soficitinib
TYK2 inhibitor
|
Soficitinib is a potent, selective tyrosine kinase 2 (TYK2) inhibitor. |
| PC-25094 |
Socrodeucitinib
TYK2 inhibitor
|
Socrodeucitinib is a potent, selective TYK2 inhibitor. |
| PC-25084 |
Quecitinib
JAK1/TYK2 inhibitor
|
Quecitinib is a potent, selective dual JAK1/TYK2 inhibitor. |
| PC-25063 |
ESK-001 hydrochloride
TYK2 inhibitor
|
ESK-001 hydrochloride (Envudeucitinib) is a novel allosteric, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 104-149 nM in human whole blood, binds to JH2 domain of TYK2. |
| PC-24937 |
Cenacitinib
TYK2 inhibitor
|
Cenacitinib (VTX 958) is a potent, highly selective, allosteric and orally bioavailable inhibitor of tyrosine kinase 2 (TYK2). |
| PC-24735 |
NMS-P953
JAK2 inhibitor
|
NMS-P953 is a potent and selective JAK2 inhibitor with IC50 of 8 nM, displays 18-, 4- and 18-fold selective over JAK1, JAK3 and TYK2 respectively. |
